This international campaign is a reminder of the seriousness of cancer, a major cause of death worldwide, leading to 8.2 million deaths in 2012. According to WHO, the annual number of new cases is expected to rise from 14 million in 2012 to 22 million in the next two decades.
Inserm researchers devote themselves to cancer research on a year-round basis, in order to reduce the mortality associated with the disease, reverse its incidence and gravity, and improve patient care.
The members of the “Immunology of Tumours and Immunotherapy” team from Inserm Unit 1015 have focused on the role of intestinal bacteria in alleviating side-effects and increasing the efficacy of an immunotherapy in oncology. Their work shows that the intestinal flora dictates the therapeutic response, offering attractive opportunities for treatment.
See press release “The intestinal flora as a complement to immunotherapy in oncology”.
Elsewhere, the researchers from the Stress and Cancer team (Inserm/Institut Curie), designated by the French National Cancer League, and directed by Fatima Mechta-Grigoriou, have taken a new step towards identifying a targeted therapy for women with an aggressive form of ovarian cancer.
 Source: Inserm
The composition of gut microbiota can predict the efficacy and tolerance of immunotherapy in people with cancer
Drug abuse and depression: towards a new understanding of brain mechanisms
(Français) Création d’un institut pluridisciplinaire pour l’étude des migrations
A molecule to regenerate insulin-producing cells in type 1 diabetic patients